| ObjectiveTo evaluate the efficacy and safety of Moxifloxacin infusion in the treatment of moderate and severe community acquired low respiratory tract infections in olders.MethodA randomized trial was comducted,64 patients with moderate severa CAP or AECB were randomly divided into 2 groups,the study group treated with Moxifloxacin 0.4 g,iv,Qd for 7～14 d;the control group with Tazocin 4.5 g,iv,Q8 h for 7～14 d.ResultsThe total effective rate,and bacterial clearance rate of the study group were 90.3%,86.7%,respectively;while the control group were 87.5%,92.3%,respectively.There was no significant difference.The side effect rate caused by moxifloxacin was 15.6%,only 1 case ceased with treatment because of clizzment.ConclusionMoxifloxacin infusion is efficient and safe. |